Shanghai, China, Sep 12^th, 2024 – BioCity Biopharma announced today that the preliminary Phase I data of BC3195 (CDH3 ADC) as a monotherapy for advanced solid tumors will be exhibited at the European Society For Medical Oncology (ESMO) Congress 2024. The ESMO Congress will be held in Barcelona, Spain , from Sep 13 to 17, 2024.

At the conference, the Company will provide a further update on the Phase I clinical progress of BC3195, the only ADC targeting CDH3(P-Cadherin) in clinical development globally, based on data presented at this year's ASCO meeting.

Detailed information is as below:

Abstract Title：

BC3195, a Novel ADC Targeting CDH3: Preliminary Results of a First-in Human Phase I Study in Patients with Advanced Solid Malignancies

Final Publication Number:1315P

Time：

12:00-13:00 CEST，on Saturday, 14 September；

Location：

Hall 6 - Poster area

Session

285 Poster session 05

About BC3195:

BC3195 is currently the only ADC targeting CDH3/P-Cadherin in clinical development globally. In preclinical studies, BC3195 binds to membrane CDH3 with strong affinity and is efficiently internalized. BC3195 is designed with a clinically validated, cleavable linker and payload (vc-MMAE) allowing for the destruction of targeted tumor cells as well as surrounding cells which is known as the bystander effect. In animal models, BC3195 demonstrated a favorable safety profile and strong antitumor activity with tumor growth inhibition of ≥100%.

BC3195 is currently undergoing concurrent Phase Ib clinical studies in China and the US. BC3195 has demonstrated a good safety profile in Phase Ia clinical studies, with confirmed PRs observed in different type tumors.

About BioCity:
Founded in December 2017, BioCity is a clinical-stage biopharmaceutical company committed to developing novel and highly differentiated, modality-independent therapeutics for cancer and autoimmune disorders including chronic kidney diseases (CKD).  The company has established a pipeline of more than 10 innovative drug candidates including small molecules, monoclonal and bispecific antibodies as well as ADCs.

Currently, BioCity Biopharma has 5 oncology assets in Phase 1 clinical development, including the first-in-class CDH3-targeting ADC and GPC3-targeting ADC, WEE1 and ATR inhibitors targeting the DNA damage response (DDR) pathway, and agents targeting the immune system, and an immune checkpoint inhibitor (TIM-3 mAb). In addition, an endothelin A (ETA)-receptor selective antagonist for CKD is in phase 2 clinical development.